DeCure for Generalized epilepsy-paroxysmal dyskinesia syndrome
DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for generalized epilepsy-paroxysmal dyskinesia syndrome — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGeneralized epilepsy-paroxysmal dyskinesia syndrome maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for generalized epilepsy-paroxysmal dyskinesia syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Three children with pathogenic ARX variants and severe movement disorders are described in a 2024 report. One child carried a novel missense variant (p.R371G). The report notes that ARX-related epilepsy-dyskinesia syndrome includes infantile epilepsy alongside a range of movement problems, from focal hand dystonia to generalised dystonia with frequent status dystonicus. The authors state that these cases illustrate diagnostic and management challenges.
A 2001 review explains that epilepsy and paroxysmal dyskinesia (PD) can be difficult to tell apart clinically. It notes that while past hypotheses suggested PD episodes might be a form of epilepsy, the current understanding is that the two disorders are distinct. A 2011 case report describes a patient with paroxysmal non-kinesigenic dyskinesia who was misdiagnosed and treated for epilepsy for decades. The authors argue that familiarity with the condition and prolonged video-EEG recordings may prevent such diagnostic delays.
A 2015 review states that paroxysmal dyskinesias represent a diagnostic challenge for neurologists working on the borderlands of psychiatry and epilepsy. It notes that clinical diagnosis remains key to treatment choice, and that psychogenic causes are common in sporadic cases, but secondary causes should not be missed. No specific drug treatment is evaluated in any of these abstracts.
What is still missing is any controlled trial data for drug treatment in this syndrome, a standardised diagnostic protocol that reliably distinguishes paroxysmal dyskinesia from epilepsy, and patient stratification by genetic subtype (such as specific ARX variants) to guide management.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Annals of Clinical and Translational Neurology · 2024 · 4 citations · open access
The spectrum of movement disorders in young children with <scp><i>ARX</i></scp>‐related <scp>epilepsy‐dyskinesia</scp> syndrome
AbstractChildren with developmental and epileptic encephalopathies often present with co-occurring dyskinesias. Pathogenic variants in ARX cause a pleomorphic syndrome that includes infantile epilepsy with a variety of movement disorders ranging from focal hand dystonia to generalized dystonia with frequent status dystonicus. In this report, we present three patients with severe movement disorders as part of ARX-associated epilepsy-dyskinesia syndrome, including a patient with a novel pathogenic missense variant (p.R371G). These cases illustrate diagnostic and management challenges of ARX-related disorder and shed light on broader challenges concerning epilepsy-dyskinesia syndromes.
Cambridge University Press eBooks · 2001 · 2 citations
Syndromes with epilepsy and paroxysmal dyskinesia
AbstractEpilepsy and paroxysmal dyskinesia (PD) may sometimes be difficult to differentiate clinically. Although for this reason in the past it has been hypothesized that episodes of PD could represent a form of epilepsy (Lishman et al., 1962; Whitty et al., 1964; Burger et al., 1972), the current understanding is that the two disorders are distinct (Fahn, 1994).
Epileptic Disorders · 2011 · 2 citations · open access
Extrapyramidal epilepsy
AbstractNon-epileptic paroxysmal movement disorders are rare extrapyramidal diseases. The clinical signs are often excluded from differential diagnosis due to their paucity on clinical examination and low prevalence. The paroxysmal, stereotypical nature of non-epileptic paroxysmal movement disorders, as well as the potential response to benzodiazepines, renders these disorders susceptible to misdiagnosis as epileptic seizures. We report a case of paroxysmal non-kinesigenic dyskinesia which was misdiagnosed and treated as epilepsy for decades. The major pathophysiological, diagnostic and therapeutic hallmarks of the disease are summarised. Familiarity and inclusion of the disease in the list of conditions that mimic epilepsy, as well as prolonged video-EEG recordings, may prevent diagnostic delays and unnecessary or belated treatments. [Published with video sequences].
Epilepsy and Paroxysmal Conditions · 2015 · 2 citations · open access
RÜLF'S CRAMP AND OTHER PAROXYSMAL DYSKINESIA
AbstractParoxysmal dyskinesia comprise a significant and fascinating part of movement disorders, which represent a diagnostic challenge for neurologists working on the borderlands of psychiatry and epilepsy. The current classification based on the relation of attacks to a movement is supported by the response to treatment and genetic difference. We reviewed clinical characteristics and the main advances in genetics of these unique, usually hereditary diseases. Clinical diagnosis remains the key to the treatment choice. Psychogenic causes are common in sporadic cases, but paroxysmal dyskinesia secondary to systemic or primary neurological disorders should not be missed and warrant careful investigation.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
